Dr Meriem Bahri is a Postdoctoral Research Associate in the Comprehensive Cancer Centre, School of Cancer & Pharmaceutical Sciences, and is a member of the Tumour Immunology Group.

Meriem's research focuses on the characterisation of chemical properties of heme oxygenase-1 inhibition for the immunotherapy treatment of cancer. Previous work has demonstrated, using in vivo models, that a small molecule inhibitor of the enzyme heme oxygenase-1 could be used to potentiate the anti-tumour immune response elicited by cytotoxic chemotherapy. The group has recently developed a pipeline to manufacture this inhibitor and Meriem will now test its chemical and physical properties, and in vivo activity.